The post Crypto Stocks Soar as US Regulators Push Ahead appeared on BitcoinEthereumNews.com. Crypto-related stocks surged on Wednesday as recent pro-crypto commentaryThe post Crypto Stocks Soar as US Regulators Push Ahead appeared on BitcoinEthereumNews.com. Crypto-related stocks surged on Wednesday as recent pro-crypto commentary

Crypto Stocks Soar as US Regulators Push Ahead

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Crypto-related stocks surged on Wednesday as recent pro-crypto commentary from the US president pushed Bitcoin and the broader crypto market higher.

Alongside a rise in the cryptocurrency market, the Bitcoin (BTC) treasury company Strategy spiked by more than 10%. Crypto exchange Coinbase registered a more than 14% gain, while miners Hut 8 clocked 13.89% and American Bitcoin Corp rose 11.65%.

Dominick John, an analyst at Zeus Research, told Cointelegraph the promise of clearer regulations on the near horizon could be one of the factors fueling the rally.

Bitcoin treasury company Strategy was one of the many crypto-related stocks to rise. Source: Google Finance 

“Crypto equities are rallying as regulatory risk is being fundamentally redefined. With the executive branch championing a clear digital asset framework, coupled with robust spot ETF inflows and the potential passage of the Clarity Act,” he said.

Wall Street’s main regulators have advanced plans to oversee the industry, with the Commodity Futures Trading Commission filing a regulatory review for prediction markets and the US Securities and Exchange Commission filing a pending application on Tuesday on Federal Securities Laws and how they govern some crypto and transactions. 

Trump’s statements helped buoy crypto

Pav Hundal, the lead analyst at Australian crypto platform Swyftx, told Cointelegraph that US President Donald Trump’s recent swipe at the banks and his push for the Senate’s crypto market structure bill to pass could also be playing a factor. 

During a roundtable at the White House on Wednesday, Trump also reiterated his support for the industry, and said in “crypto, we want to be dominant; we want to be dominant in everything we do.”

“The market is putting a policy premium in the tape right now, and it is inflating crypto stocks,” Hundal said.

“We’ve got a double whammy of Trump pushing Congress on legislation and picking a fight with US banks for dragging their heels over the CLARITY Act. Coinbase is basically the cleanest large-cap expression of that in US equities,” he added. 

Rally could still cool on bad news

The wider crypto market has also experienced a spike. Bitcoin has jumped over 7.6% in the last 24 hours to trade at $72,866, according to CoinGecko, while Ether (ETH) is up more than 8.3%, trading at $2,132.

However, Hundal cautioned that if the expected regulatory progress stalls or Bitcoin drops, the stock rally could halt and retreat as well.

Related: Trump sends pro-Bitcoin Fed chair nomination to the Senate

“Crypto stocks are obviously rallying on the expectation of political progress, and there is no reason that couldn’t continue. But things change quickly with this White House. If we see this regulatory debate go stale, or hit a wall, or Bitcoin is hit, it’s not hard to imagine a correction,” he said.

Magazine: Would Bitcoin really be at $200K if not for Jane Street? Trade Secrets

Cointelegraph is committed to independent, transparent journalism. This news article is produced in accordance with Cointelegraph’s Editorial Policy and aims to provide accurate and timely information. Readers are encouraged to verify information independently. Read our Editorial Policy https://cointelegraph.com/editorial-policy

Source: https://cointelegraph.com/news/crypto-stocks-rally-trump-regulation-bitcoin-surge?utm_source=rss_feed&utm_medium=feed&utm_campaign=rss_partner_inbound

Market Opportunity
OFFICIAL TRUMP Logo
OFFICIAL TRUMP Price(TRUMP)
$3.085
$3.085$3.085
-1.43%
USD
OFFICIAL TRUMP (TRUMP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09